O	0	11	Neutropenia
O	12	22	management
O	23	27	with
B-intervention	28	39	palbociclib
O	40	42	in
B-ethinicity	43	51	Japanese
O	52	60	patients
O	61	65	with
O	66	74	advanced
O	75	81	breast
O	82	88	cancer
O	88	89	.

O	90	93	The
O	94	100	cyclin
O	100	101	-
O	101	110	dependent
O	111	117	kinase
O	118	119	4
O	119	120	/
O	120	121	6
O	122	123	(
O	123	127	CDK4
O	127	128	/
O	128	129	6
O	129	130	)
O	131	140	inhibitor
O	141	152	palbociclib
O	152	153	,
O	154	156	in
O	157	168	combination
O	169	173	with
O	174	183	endocrine
O	184	191	therapy
O	192	193	(
O	193	195	ET
O	195	196	)
O	196	197	,
O	198	211	significantly
O	212	221	prolonged
O	222	233	progression
O	233	234	-
O	234	238	free
O	239	247	survival
O	248	250	in
O	251	256	women
O	257	261	with
O	262	269	hormone
O	270	278	receptor
O	278	279	-
O	279	287	positive
O	287	288	,
O	289	294	human
O	295	304	epidermal
O	305	311	growth
O	312	318	factor
O	319	327	receptor
O	328	329	2
O	329	330	-
O	330	338	negative
O	339	347	advanced
O	348	354	breast
O	355	361	cancer
O	362	363	(
O	363	365	HR
O	365	366	+
O	366	367	/
O	367	371	HER2
O	371	372	-
O	373	376	ABC
O	376	377	)
O	378	380	in
O	381	387	PALOMA
O	387	388	-
O	388	389	2
O	390	393	and
O	394	400	PALOMA
O	400	401	-
O	401	402	3
O	402	403	.

O	404	415	Neutropenia
O	416	419	and
O	420	431	palbociclib
O	432	436	dose
O	437	447	reductions
O	447	448	/
O	448	461	interruptions
O	462	470	occurred
O	471	475	more
O	476	486	frequently
O	487	489	in
O	490	493	the
O	494	502	Japanese
O	503	509	versus
O	510	517	overall
O	518	529	populations
O	529	530	.

O	531	533	We
O	534	543	evaluated
O	544	555	neutropenia
O	556	564	patterns
O	564	565	,
O	566	577	palbociclib
O	578	582	dose
O	583	593	management
O	593	594	,
O	595	598	and
O	599	607	clinical
O	608	617	responses
O	618	623	after
O	624	628	dose
O	629	638	reduction
O	639	641	in
O	642	650	Japanese
O	651	659	patients
O	660	662	in
O	663	669	PALOMA
O	669	670	-
O	670	671	2
O	672	675	and
O	676	682	PALOMA
O	682	683	-
O	683	684	3
O	685	688	and
O	689	690	a
O	691	697	single
O	697	698	-
O	698	701	arm
O	702	710	Japanese
O	711	716	phase
O	717	718	2
O	719	724	study
O	724	725	.

O	726	732	PALOMA
O	732	733	-
O	733	734	2
O	735	738	and
O	739	742	the
O	743	751	Japanese
O	752	757	phase
O	758	759	2
O	760	765	study
O	766	774	enrolled
B-eligibility	775	789	postmenopausal
I-eligibility	790	795	women
I-eligibility	796	800	with
I-eligibility	801	809	estrogen
I-eligibility	810	818	receptor
I-eligibility	818	819	-
I-eligibility	819	827	positive
I-eligibility	827	828	,
I-eligibility	829	833	HER2
I-eligibility	833	834	-
I-eligibility	835	838	ABC
I-eligibility	839	842	who
I-eligibility	843	846	had
I-eligibility	847	850	not
I-eligibility	851	859	received
I-eligibility	860	865	prior
I-eligibility	866	874	systemic
I-eligibility	875	882	therapy
I-eligibility	883	886	for
I-eligibility	887	895	advanced
I-eligibility	896	903	disease
O	903	904	;
O	905	911	PALOMA
O	911	912	-
O	912	913	3
O	914	922	enrolled
O	923	928	women
O	929	933	with
O	934	936	HR
O	936	937	+
O	937	938	/
O	938	942	HER2
O	942	943	-
O	944	947	ABC
O	947	948	,
O	949	959	regardless
O	960	962	of
O	963	973	menopausal
O	974	980	status
O	980	981	,
O	982	987	whose
O	988	995	disease
O	996	999	had
O	1000	1010	progressed
O	1011	1016	after
O	1017	1022	prior
O	1023	1025	ET
O	1025	1026	.

O	1027	1038	Palbociclib
O	1039	1040	(
O	1040	1043	125
O	1044	1046	mg
O	1046	1047	/
O	1047	1050	day
O	1050	1051	)
O	1052	1055	was
O	1056	1068	administered
O	1069	1070	3
O	1071	1076	weeks
O	1077	1079	on
O	1079	1080	/
O	1080	1081	1
O	1082	1086	week
O	1087	1090	off
O	1090	1091	.

O	1092	1096	Dose
O	1097	1106	reduction
O	1106	1107	/
O	1107	1119	interruption
O	1119	1120	,
O	1121	1126	cycle
O	1127	1132	delay
O	1132	1133	,
O	1134	1139	tumor
O	1140	1148	response
O	1148	1149	,
O	1150	1153	and
O	1154	1164	laboratory
O	1164	1165	-
O	1165	1173	assessed
O	1174	1185	neutropenia
O	1186	1190	were
O	1191	1199	analyzed
O	1200	1202	in
O	1203	1211	Japanese
O	1212	1220	patients
O	1221	1224	who
O	1225	1233	received
O	1234	1245	palbociclib
O	1245	1246	.

O	1247	1248	A
O	1249	1254	total
O	1255	1257	of
B-total-participants	1258	1261	101
O	1262	1270	Japanese
O	1271	1279	patients
O	1280	1288	received
O	1289	1300	palbociclib
O	1301	1302	+
O	1303	1305	ET
O	1305	1306	.

O	1307	1312	Among
O	1313	1321	Japanese
O	1322	1330	patients
O	1331	1333	in
O	1334	1337	the
O	1338	1339	3
O	1340	1347	studies
O	1347	1348	,
O	1349	1352	the
O	1353	1362	frequency
O	1363	1365	of
B-outcome	1366	1369	all
I-outcome	1369	1370	-
I-outcome	1370	1375	grade
I-outcome	1375	1376	/
I-outcome	1376	1381	grade
I-outcome	1382	1383	3
I-outcome	1383	1384	/
I-outcome	1384	1389	grade
I-outcome	1390	1391	4
I-outcome	1392	1403	neutropenia
O	1404	1407	was
B-iv-bin-percent	1408	1410	94
I-iv-bin-percent	1410	1411	%
O	1411	1412	/
B-iv-bin-percent	1412	1414	53
I-iv-bin-percent	1414	1415	%
O	1415	1416	/
B-iv-bin-percent	1416	1418	34
I-iv-bin-percent	1418	1419	%
O	1419	1420	,
B-iv-bin-percent	1421	1424	100
I-iv-bin-percent	1424	1425	%
O	1425	1426	/
B-iv-bin-percent	1426	1428	69
I-iv-bin-percent	1428	1429	%
O	1429	1430	/
B-iv-bin-percent	1430	1432	21
I-iv-bin-percent	1432	1433	%
O	1433	1434	,
O	1435	1438	and
B-iv-bin-percent	1439	1442	100
I-iv-bin-percent	1442	1443	%
O	1443	1444	/
B-iv-bin-percent	1444	1446	67
I-iv-bin-percent	1446	1447	%
O	1447	1448	/
B-iv-bin-percent	1448	1450	26
I-iv-bin-percent	1450	1451	%
O	1451	1452	,
O	1453	1465	respectively
O	1465	1466	.

B-iv-bin-abs	1467	1473	Twenty
O	1474	1475	(
B-iv-bin-percent	1475	1477	63
I-iv-bin-percent	1477	1478	%
O	1478	1479	)
O	1479	1480	,
B-iv-bin-abs	1481	1483	28
O	1484	1485	(
B-iv-bin-percent	1485	1487	67
I-iv-bin-percent	1487	1488	%
O	1488	1489	)
O	1489	1490	,
O	1491	1494	and
B-iv-bin-abs	1495	1497	15
O	1498	1499	(
B-iv-bin-percent	1499	1501	56
I-iv-bin-percent	1501	1502	%
O	1502	1503	)
O	1504	1512	patients
B-outcome	1513	1521	required
I-outcome	1522	1533	palbociclib
I-outcome	1534	1538	dose
I-outcome	1539	1548	reduction
O	1548	1549	.

O	1550	1554	Dose
O	1555	1567	interruption
O	1568	1570	or
O	1571	1580	reduction
O	1581	1584	did
O	1585	1588	not
O	1589	1595	affect
O	1596	1607	palbociclib
O	1608	1617	treatment
O	1618	1626	duration
O	1626	1627	,
O	1628	1631	and
O	1632	1639	durable
O	1640	1645	tumor
O	1646	1654	response
O	1655	1658	was
O	1659	1667	observed
O	1668	1675	despite
O	1676	1680	dose
O	1681	1690	reduction
O	1690	1691	.

O	1692	1703	Neutropenia
O	1704	1707	was
O	1708	1718	manageable
O	1719	1723	with
O	1724	1728	dose
O	1729	1742	modifications
O	1742	1743	,
O	1744	1751	without
O	1752	1761	affecting
O	1762	1773	palbociclib
O	1774	1783	treatment
O	1784	1792	duration
O	1793	1795	or
O	1796	1804	efficacy
O	1804	1805	.

O	1806	1812	Pfizer
O	1813	1814	(
O	1814	1825	NCT01740427
O	1825	1826	,
O	1827	1838	NCT01684215
O	1838	1839	,
O	1840	1851	NCT01942135
O	1851	1852	)
O	1852	1853	.
